Could a Weight-Loss drug slow endometrial cancer growth?
NCT ID NCT07065552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with obesity-driven endometrial cancer. About 20 participants will take the drug before their scheduled hysterectomy. Researchers will compare cancer cell activity in tissue samples taken before and after treatment to see if the drug reduces tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?